What is the recommended treatment for cocaine and methamphetamine use disorder?

Treatment for Cocaine and Methamphetamine Use Disorder

The combination of contingency management (CM) plus community reinforcement approach (CRA) is the most effective treatment for both cocaine and methamphetamine use disorder, demonstrating superior outcomes in achieving abstinence both short-term and long-term compared to all other interventions. 1

Primary Recommendation: Combined Behavioral Intervention

The evidence unequivocally supports CM + CRA as first-line treatment for stimulant use disorders. This combination:

• Increases abstinence rates nearly 3-fold at end of treatment (OR 2.84) and over 7-fold at 12 weeks (OR 7.60) compared to treatment as usual 1
• Maintains superiority at longest follow-up (OR 3.08), demonstrating durability of effect 1
• Reduces treatment dropout significantly (OR 3.92 at 12 weeks and 3.63 at end of treatment) 1
• Outperforms CBT alone, CM alone, and all other single interventions in head-to-head comparisons 1

What These Interventions Entail:

Contingency Management (CM): Provides tangible rewards (vouchers, prizes) contingent upon objective evidence of drug-free urine samples. This creates immediate positive reinforcement for abstinence.

Community Reinforcement Approach (CRA): A comprehensive multi-component intervention including:

• Functional analysis of drug use triggers
• Coping skills training
• Social and familial relationship counseling
• Recreational activity planning
• Vocational counseling and support

Alternative Psychosocial Options (When CM + CRA Unavailable)

If the combined approach is not accessible, the hierarchy of alternatives based on evidence quality is:

1. CRA alone - More effective than non-contingent rewards, supportive therapy, treatment as usual, and 12-step programs at long-term follow-up 1
2. CM alone - Moderately effective short-term but less durable than combined approach 1, 2
3. CBT groups - Effective for cocaine use compared to treatment as usual 2

Pharmacological Considerations

There are currently NO FDA-approved medications for cocaine or methamphetamine use disorder 1, 3. However, emerging evidence suggests:

For Cocaine Use Disorder:

• Prescription amphetamines (mixed amphetamine salts, lisdexamphetamine, dextroamphetamine) show promise, particularly at higher doses (RR 2.44 for sustained abstinence; moderate-quality evidence) 4
• Disulfiram shows promise in some studies 3
• Methylphenidate evidence remains inconclusive overall, though may benefit patients with comorbid ADHD 5

For Methamphetamine Use Disorder:

• Long-acting methylphenidate received a conditional recommendation from 2024 ASAM/AAAP guidelines, though based on low-certainty evidence 6
• Mirtazapine shows promise 3
• CM interventions appear effective relative to standard treatment 2

Critical Caveat on Pharmacotherapy:

The 2026 meta-analysis of 12 NIDA-sponsored trials found no significant pooled treatment effect for various pharmacotherapies (topiramate, bupropion, modafinil, ondansetron, tiagabine, cabergoline, reserpine, selegiline, baclofen) on either reduced use or abstinence outcomes 7. Only cabergoline showed individual positive effect for reduced cocaine use. This underscores that psychosocial interventions remain the evidence-based foundation of treatment.

Implementation Algorithm

Step 1: Initiate CM + CRA as first-line treatment

• Establish objective monitoring (urine drug screens 2-3x weekly initially)
• Implement immediate reward system for negative screens
• Begin comprehensive CRA components simultaneously

Step 2: If CM + CRA unavailable, implement CRA alone or CM alone (in that order of preference)

Step 3: Consider adjunctive pharmacotherapy ONLY in specific contexts:

• For cocaine use disorder with treatment-refractory cases: Consider prescription amphetamines at robust doses under close monitoring
• For methamphetamine use disorder with comorbid ADHD: Consider long-acting methylphenidate with structured behavioral engagement framework 6
• Monitor cardiovascular parameters strictly if using stimulant medications (up to 90 mg/day methylphenidate studied) 5

Step 4: Avoid relying solely on:

• CBT alone (inferior to CM + CRA) 1
• 12-step programs alone (inferior to CM + CRA) 1
• Pharmacotherapy alone (insufficient evidence) 7

Common Pitfalls to Avoid

1. Using abstinence as the only outcome measure: Reduced use (transition from ≥5 days/month to 1-4 days/month) is a meaningful outcome associated with improved health and may identify treatment signals missed by abstinence-only criteria 7

2. Implementing CM without adequate reward magnitude: The intervention requires tangible, meaningful incentives to be effective

3. Prescribing stimulant medications without structured monitoring: If considering pharmacotherapy, implement a behavioral engagement framework assessing adherence, abstinence progress, attendance, alternative activities, and support access 6

4. Expecting pharmacotherapy to work as monotherapy: Even when medications are used, they must be combined with psychosocial interventions 1, 3

5. Treating cocaine and methamphetamine use disorders differently: Current evidence shows no differential treatment effect between these stimulants for psychosocial interventions 8

Evidence Strength and Nuances

The 2018 PLoS Medicine network meta-analysis 1 represents the highest quality evidence available, analyzing 50 RCTs with 6,942 participants. This guideline-level evidence explicitly states it "should inform patients, clinicians, and policy-makers" and recommends that "clinical guidelines should be updated to reflect these results."

The main limitation acknowledged is lack of blinding in behavioral interventions, but outcomes were objective (urine toxicology), minimizing bias. The evidence strength ranged from high to very low across different comparisons, with the CM + CRA combination showing the most consistent and robust effects.